Free Trial

Ventyx Biosciences (VTYX) Competitors

Ventyx Biosciences logo
$2.08 +0.04 (+1.96%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.16 +0.08 (+3.80%)
As of 07:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTYX vs. ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, STOK, SANA, MRVI, and URGN

Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.

Ventyx Biosciences vs. Its Competitors

AnaptysBio (NASDAQ:ANAB) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

97.9% of Ventyx Biosciences shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AnaptysBio presently has a consensus price target of $42.38, suggesting a potential upside of 74.74%. Ventyx Biosciences has a consensus price target of $10.00, suggesting a potential upside of 380.77%. Given Ventyx Biosciences' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AnaptysBio
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.80
Ventyx Biosciences
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, AnaptysBio had 4 more articles in the media than Ventyx Biosciences. MarketBeat recorded 4 mentions for AnaptysBio and 0 mentions for Ventyx Biosciences. AnaptysBio's average media sentiment score of 0.86 beat Ventyx Biosciences' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company Overall Sentiment
AnaptysBio Positive
Ventyx Biosciences Neutral

Ventyx Biosciences has a net margin of 0.00% compared to AnaptysBio's net margin of -125.70%. Ventyx Biosciences' return on equity of -47.45% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
AnaptysBio-125.70% -282.47% -30.79%
Ventyx Biosciences N/A -47.45%-43.49%

Ventyx Biosciences has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$91.28M7.81-$145.23M-$4.85-5.00
Ventyx BiosciencesN/AN/A-$135.12M-$1.75-1.19

AnaptysBio has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

AnaptysBio and Ventyx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Ventyx Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTYX vs. The Competition

MetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$145.17M$2.87B$5.47B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-1.1920.8026.9920.11
Price / SalesN/A286.31428.71119.81
Price / CashN/A41.1936.8257.86
Price / Book0.587.487.985.56
Net Income-$135.12M-$55.04M$3.16B$248.40M
7 Day Performance2.97%2.44%2.38%4.67%
1 Month Performance-18.75%1.90%2.17%6.64%
1 Year Performance-11.11%4.35%33.81%21.31%

Ventyx Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTYX
Ventyx Biosciences
2.3679 of 5 stars
$2.08
+2.0%
$10.00
+380.8%
-9.2%$145.17MN/A-1.1930
ANAB
AnaptysBio
2.2778 of 5 stars
$22.20
-1.2%
$42.38
+90.9%
-4.8%$660.18M$91.28M-4.58100
IMTX
Immatics
2.4191 of 5 stars
$5.38
-0.9%
$14.67
+172.6%
-52.6%$660.02M$168.65M-31.65260
TRVI
Trevi Therapeutics
3.1262 of 5 stars
$5.47
-2.7%
$20.29
+270.9%
+115.4%$659.19MN/A-12.1620
NUVB
Nuvation Bio
3.4338 of 5 stars
$1.96
+1.3%
$7.17
+266.6%
-34.3%$656.71M$7.87M-0.8360High Trading Volume
DAWN
Day One Biopharmaceuticals
1.7109 of 5 stars
$6.50
+0.5%
$30.57
+370.3%
-55.3%$655.82M$131.16M-9.1560
GHRS
GH Research
1.5694 of 5 stars
$12.19
-2.0%
$32.00
+162.5%
+31.8%$647.23MN/A-15.4310
STOK
Stoke Therapeutics
3.9931 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-7.2%$634.96M$190.91M14.37100
SANA
Sana Biotechnology
2.5683 of 5 stars
$2.73
-2.8%
$8.60
+215.0%
-23.4%$633.59MN/A-3.10380Gap Up
MRVI
Maravai LifeSciences
3.727 of 5 stars
$2.41
-2.4%
$6.64
+175.5%
-62.4%$629.01M$259.18M-2.11610
URGN
Urogen Pharma
4.5452 of 5 stars
$13.70
+1.6%
$32.86
+139.8%
-14.8%$621.99M$90.40M-4.31200Analyst Forecast

Related Companies and Tools


This page (NASDAQ:VTYX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners